On May 27, 2020 Biodesix, Inc., a leading diagnostic company in lung disease, recently published three clinical research abstracts, which reported valuable new information regarding treatment of patients in the lung cancer continuum of care (Press release, Biodesix, MAY 27, 2020, View Source [SID1234558580]). The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), and American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract #A4465: First Look at the Distribution of Risk of Malignancy Pre and Post-Test Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study
Published: ATS, American Journal of Respiratory and Critical Care Medicine, May 1
An abstract published by Michael Pritchett, DO, MPH of Pinehurst Medical Clinic reports findings from the ORACLE observational study (NCT03766958), which highlights the use of the Nodify XL2 test. The data suggest that using blood-based biomarkers integrated with clinical risk factors to calculate risk of malignancy for solitary pulmonary nodules may be important in helping guide physicians in determining treatment strategy, including potentially reducing performance of invasive procedures on benign nodules. Dr. Pritchett will present the data in a webinar on June 18.
Abstract #9545: Real-World Performance of Blood-Based Host Immune Profiling in First-line Immunotherapy Treatment in Advanced Stage Non-Small Cell Lung Cancer
Published: ASCO (Free ASCO Whitepaper) Virtual Annual Meeting, Journal of Clinical Oncology, May 13
An abstract published by R. Brian Mitchell, M.D. of Virginia Cancer Institute reports data from the interim analysis of the ongoing INSIGHT clinical study (NCT03289780). The data suggest that blood-based host immune profiling can provide clinically significant information to predict outcomes and guide treatment choices made by physicians for patients with advanced non-small cell lung cancer eligible for immune checkpoint inhibitor therapy. This abstract will be available as an e-poster at ASCO (Free ASCO Whitepaper)’s upcoming annual meeting. Wallace Akerley, M.D. of Huntsman Cancer Institute will present the data in a webinar on June 3.
Abstract # 3101 / 11: Utility of a New Targeted Next Generation Sequencing Test for Liquid Biopsy Samples from Patients with NSCLC
Published: AACR (Free AACR Whitepaper) Virtual Annual Meeting II, May 15
In an abstract published by Hestia Mellert, Ph.D., of Biodesix, data suggest that a newly-developed blood-based next generation sequencing test method supports the usefulness of molecular detection of actionable and emerging biomarkers in a liquid biopsy. The abstract will be available as an e-poster at AACR (Free AACR Whitepaper)’s Virtual Annual Meeting II. Dr. Mellert will present the data from the poster in a webinar on June 25.
"Acceptance of these abstracts, especially at three of the most important events in oncology and pulmonology, is extremely meaningful for Biodesix. It is a testament to the value of our research, and our commitment to delivering actionable results," said Scott Hutton, Chief Executive Officer of Biodesix. "The data presented in these abstracts represent another step for Biodesix in solving complex diagnostic challenges in lung disease, and we’re tremendously proud to share that."